Li Wei, Mao Song, Wu Liangxia, Shi Wenjing, Zhang Jianhua, Wang Zhong
Department of General Surgery, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Department of Pediatrics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Crit Rev Eukaryot Gene Expr. 2019;29(1):85-94. doi: 10.1615/CritRevEukaryotGeneExpr.2019025311.
Plasminogen activator inhibitor type 1 (PAI-1) correlates with the risk and progression of systemic lupus erythematosus (SLE). We aimed to assess the relationship between the PAI-1 4G/5G gene polymorphism and SLE/lupus nephritis risk. We identified the eligible studies regarding the association between the PAI-1 4G/5G gene polymorphism and the risk of SLE/lupus nephritis. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a fixed-effects model or, in the presence of heterogeneity, a random-effects model. A total of six studies were enrolled in our pooled analysis. The PAI-1 4G/5G gene polymorphism had no significant association with the risk of SLE among overall populations, Asians and Caucasians. Nor was it associated with susceptibility to lupus nephritis among overall populations, Asians and Caucasians. Sensitivity analysis yielded similar results. No marked publication bias was noted. In conclusion, the PAI-1 4G/5G gene polymorphism is not associated with susceptibility to SLE/lupus nephritis among overall populations, Asians and Caucasians. However, more studies should be conducted in the future.
纤溶酶原激活物抑制剂1型（PAI-1）与系统性红斑狼疮（SLE）的风险及病情进展相关。我们旨在评估PAI-1 4G/5G基因多态性与SLE/狼疮性肾炎风险之间的关系。我们确定了有关PAI-1 4G/5G基因多态性与SLE/狼疮性肾炎风险关联的合格研究。使用固定效应模型计算比值比（OR）和95%置信区间（CI），若存在异质性，则使用随机效应模型。共有六项研究纳入我们的汇总分析。PAI-1 4G/5G基因多态性与总体人群、亚洲人和高加索人中SLE的风险无显著关联。它与总体人群、亚洲人和高加索人中狼疮性肾炎的易感性也无关联。敏感性分析得出了相似结果。未发现明显的发表偏倚。总之，PAI-1 4G/5G基因多态性与总体人群、亚洲人和高加索人中SLE/狼疮性肾炎的易感性无关。然而，未来应开展更多研究。
